Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT (saltuzumab lukang) plus osimertinib induction in unresectable stage III EGFR-mutated NSCLC
ChiCTR2600129342Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan and osimertinib in non-small cell lung cancer (NSCLC), sponsored by Peking University People's Hospital. Primary endpoint: Objective response rate (ORR) at 12 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sacituzumab govitecanosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600129342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129342.